Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.840
-0.120 (-6.12%)
Oct 10, 2025, 11:05 AM EDT - Market open

Acrivon Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
25.3225.2121.088.712.47
Research & Development
69.0963.9946.0223.9513.72
Total Operating Expenses
94.4189.267.132.6616.18
Operating Income
-94.41-89.2-67.1-32.66-16.18
Interest Income
8.799.27.04--
Other Non-Operating Income (Expense)
--0.56-0.32--0.06
Total Non-Operating Income (Expense)
8.798.646.72--0.06
Pretax Income
-85.62-80.56-60.39-32.66-16.24
Net Income
-85.96-80.56-60.39-31.17-16.24
Net Income to Common
-85.96-80.56-60.39-31.17-16.24
Shares Outstanding (Basic)
38342242
Shares Outstanding (Diluted)
38342242
Shares Change (YoY)
48.58%53.05%435.63%136.43%-
EPS (Basic)
-2.19-2.38-2.74-7.56-9.32
EPS (Diluted)
-2.19-2.38-2.74-7.56-9.32
Free Cash Flow
-73.2-68.44-43.93-32.28-14.22
Free Cash Flow Per Share
-1.91-2.03-1.99-7.83-8.16
EBITDA
-93.21-88.19-66.57-32.29-16.15
EBIT
-94.41-89.2-67.1-32.66-16.18
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q